TVGN
Semper Paratus Acquisition Corp.
NASDAQ · Healthcare · Biotechnology · US
$7.10
+0.42%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +32.0%
- EBIT
- +31.5%
- EPS
- +36.1%
- Free cash flow
- +12.9%
- Operating cash flow
- +13.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- -94.6%
- EBIT
- +51.2%
- Net income
- —
- EPS
- -72.6%
- Free cash flow
- -3.3%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026